{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:42:32Z","timestamp":1778110952030,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10662-5","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T03:44:53Z","timestamp":1749440693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of Rs228648 and Rs2890565 single nucleotide polymorphisms in Urotensin-2 gene in prostate cancer"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2963-5213","authenticated-orcid":false,"given":"Fatma","family":"Sertgoz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4757-803X","authenticated-orcid":false,"given":"Ozgur","family":"Efiloglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9157-8662","authenticated-orcid":false,"given":"Emrah","family":"Nikerel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-971X","authenticated-orcid":false,"given":"Asif","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-6533","authenticated-orcid":false,"given":"Dilek","family":"Telci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"10662_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"10662_CR2","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1101\/gad.819500","volume":"14","author":"C Abate-Shen","year":"2000","unstructured":"Abate-Shen C, Shen MM (2000) Molecular genetics of prostate cancer. Genes Dev 14:2410\u20132434","journal-title":"Genes Dev"},{"key":"10662_CR3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K et al (2023) 2022 update on prostate Cancer epidemiology and risk Factors\u2014A systematic review. Eur Urol 84:191\u2013206","journal-title":"Eur Urol"},{"key":"10662_CR4","doi-asserted-by":"crossref","unstructured":"Batura D, Patel A, Gandhi A, Pradhan A, Samsara B, Tetea A, Bassett A (2023) P, Giles Hellawell \u00b7 Ethnic differences in prostate cancer presentation: a time for testing advocacy. 41:3543\u20133549","DOI":"10.1007\/s00345-023-04644-0"},{"key":"10662_CR5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bjc.2011.273","volume":"105","author":"P Kheirandish","year":"2011","unstructured":"Kheirandish P, Chinegwundoh F (2011) Ethnic differences in prostate cancer. Br J Cancer 105:481\u2013485","journal-title":"Br J Cancer"},{"key":"10662_CR6","doi-asserted-by":"publisher","unstructured":"Okoye JO (2020) High mortality risk of prostate cancer patients in Asia and West africa: A systematic review. https:\/\/doi.org\/10.4103\/ajm.ajm_19_20","DOI":"10.4103\/ajm.ajm_19_20"},{"key":"10662_CR7","doi-asserted-by":"crossref","first-page":"155326","DOI":"10.1016\/j.metabol.2022.155326","volume":"137","author":"SC Larsson","year":"2022","unstructured":"Larsson SC, Spyrou N, Mantzoros CS (2022) Body fatness associations with cancer: evidence from recent epidemiological studies and future directions. Metabolism 137:155326","journal-title":"Metabolism"},{"key":"10662_CR8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2022.03.033","volume":"83","author":"SHJ Jochems","year":"2023","unstructured":"Jochems SHJ, Fritz J, H\u00e4ggstr\u00f6m C, J\u00e4rvholm B, Stattin P, Stocks T (2023) Smoking and risk of prostate Cancer and prostate Cancer death: A pooled study. Eur Urol 83:422\u2013431","journal-title":"Eur Urol"},{"key":"10662_CR9","first-page":"3868","volume":"13","author":"KS Allemailem","year":"2021","unstructured":"Allemailem KS, Almatroudi A, Alrumaihi F et al (2021) Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res 13:3868\u20133889","journal-title":"Am J Transl Res"},{"key":"10662_CR10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/07357907.2023.2291776","volume":"42","author":"DF Mendivelso Gonz\u00e1lez","year":"2024","unstructured":"Mendivelso Gonz\u00e1lez DF, S\u00e1nchez Villalobos SA, Ramos AE, Montero Ovalle WJ, Serrano L\u00f3pez ML (2024) Single nucleotide polymorphisms associated with prostate Cancer progression: A systematic review. Cancer Invest 42:75\u201396","journal-title":"Cancer Invest"},{"key":"10662_CR11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/14081","volume":"1","author":"HP Nothacker","year":"1999","unstructured":"Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O\u2019Dowd B, Duckles SP, Civelli O (1999) Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1:383\u2013385","journal-title":"Nat Cell Biol"},{"key":"10662_CR12","doi-asserted-by":"crossref","first-page":"101074","DOI":"10.1016\/j.cpcardiol.2021.101074","volume":"47","author":"A Avagimyan","year":"2022","unstructured":"Avagimyan A, Kajaia A, Gabunia L, Ghambashidze K, Sulashvili N, Ratiani L, Heshmat-Ghahdarijani K, Sheibani M, Aznauryan A (2022) Urotensin-II as a promising Key-Point of cardiovascular disturbances sequel. Curr Probl Cardiol 47:101074","journal-title":"Curr Probl Cardiol"},{"key":"10662_CR13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","volume":"401","author":"RS Ames","year":"1999","unstructured":"Ames RS, Sarau HM, Chambers JK et al (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282\u2013286","journal-title":"Nature"},{"key":"10662_CR14","doi-asserted-by":"crossref","first-page":"249656","DOI":"10.3389\/fendo.2017.00076","volume":"8","author":"H Castel","year":"2017","unstructured":"Castel H, Desrues L, Joubert JE, Tonon MC, Pr\u00e9zeau L, Chabbert M, Morin F, Gandolfo P (2017) The G protein-coupled receptor UT of the neuropeptide Urotensin II displays structural and functional chemokine features. Front Endocrinol (Lausanne) 8:249656","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10662_CR15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(99)01003-0","volume":"457","author":"Y Coulouarn","year":"1999","unstructured":"Coulouarn Y, J\u00e9gou S, Tostivint H, Vaudry H, Lihrmann I (1999) Cloning, sequence analysis and tissue distribution of the mouse and rat Urotensin II precursors. FEBS Lett 457:28\u201332","journal-title":"FEBS Lett"},{"key":"10662_CR16","doi-asserted-by":"crossref","first-page":"15803","DOI":"10.1073\/pnas.95.26.15803","volume":"95","author":"Y Coulouarn","year":"1998","unstructured":"Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H (1998) Cloning of the cDNA encoding the Urotensin II precursor in frog and human reveals intense expression of the Urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 95:15803\u201315808","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10662_CR17","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/00004872-200112000-00011","volume":"19","author":"M Matsushita","year":"2001","unstructured":"Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y (2001) Co-expression of Urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19:2185\u20132190","journal-title":"J Hypertens"},{"key":"10662_CR18","doi-asserted-by":"crossref","first-page":"103594","DOI":"10.1016\/j.jpet.2025.103594","volume":"392","author":"X Zhang","year":"2025","unstructured":"Zhang X, Chen Z, Cao J, Zhou P, Zhang Z, Sun X, Liu Y, Li T, Cheng H-J, Cheng CP (2025) Enhanced negative modulation of Urotensin II on cardiac function and [Ca2+]i regulation in a diabetic rat model: insights into molecular and cellular mechanisms. J Pharmacol Exp Ther 392:103594","journal-title":"J Pharmacol Exp Ther"},{"key":"10662_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.120.265496","volume":"374","author":"ML Ozoux","year":"2020","unstructured":"Ozoux ML, Briand V, Pelat M et al (2020) Potential therapeutic value of Urotensin II receptor antagonist in chronic kidney disease and associated comorbidities. J Pharmacol Exp Ther 374:24\u201337","journal-title":"J Pharmacol Exp Ther"},{"key":"10662_CR20","doi-asserted-by":"publisher","unstructured":"Michael O, Kanthakumar P, Soni H, Lenin R, Jha KA, Gangaraju R, Adebiyi A (2024) Upregulation of the Urotensin II system in diabetic kidney disease includes Urotensin. https:\/\/doi.org\/10.1152\/PHYSIOL.2024.39.S1.1002. II-Related Peptide. https:\/\/doi.org\/101152\/physiol202439S11002","DOI":"10.1152\/PHYSIOL.2024.39.S1.1002"},{"key":"10662_CR21","doi-asserted-by":"crossref","unstructured":"Sabarathinam S (2024) Targeting Urotensin II with silymarin: potential therapeutic strategies for diabetes and associated cardiovascular complications. Phytochem Rev 1\u201313","DOI":"10.1007\/s11101-024-10044-y"},{"key":"10662_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA60111750","author":"M Kilinc","year":"2024","unstructured":"Kilinc M, Demir I, Aydemir S, Gul R, Dokuyucu R (2024) Elevated Urotensin-II and TGF-\u03b2 levels in COPD: biomarkers of fibrosis and airway remodeling in smokers. Med (Lithuania). https:\/\/doi.org\/10.3390\/MEDICINA60111750","journal-title":"Med (Lithuania)"},{"key":"10662_CR23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.38053\/acmj.1330608","volume":"5","author":"Y KARAKU\u015e","year":"2023","unstructured":"KARAKU\u015e Y, A\u00c7IKG\u00d6Z N (2023) Inquiring about the link between urotensin-II and coronary collateral development in coronary artery patients with and without diabetes. Anatol Curr Med J 5:371\u2013375","journal-title":"Anatol Curr Med J"},{"key":"10662_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-33-48","volume":"33","author":"R Franco","year":"2014","unstructured":"Franco R, Zappavigna S, Gigantino V et al (2014) Urotensin II receptor determines prognosis of bladder cancer regulating cell motility\/invasion. J Experimental Clin Cancer Res 33:1\u201310","journal-title":"J Experimental Clin Cancer Res"},{"key":"10662_CR25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/pros.23734","volume":"79","author":"R Giulianelli","year":"2019","unstructured":"Giulianelli R, Nardoni S, Bruzzese D et al (2019) Urotensin II receptor expression in prostate cancer patients: A new possible marker. Prostate 79:288\u2013294","journal-title":"Prostate"},{"key":"10662_CR26","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.peptides.2004.03.028","volume":"25","author":"T Yoshimoto","year":"2004","unstructured":"Yoshimoto T, Matsushita M, Hirata Y (2004) Role of Urotensin II in peripheral tissue as an autocrine\/paracrine growth factor. Peptides (NY) 25:1775\u20131781","journal-title":"Peptides (NY)"},{"key":"10662_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-26890-9","volume":"13","author":"J Sun","year":"2023","unstructured":"Sun J, Zhou J, Sun S, Lin H, Zhang H, Zhong Z, Chi J, Guo HY (2023) Protective effect of Urotensin II receptor antagonist urantide and exercise training on doxorubicin-induced cardiotoxicity. Sci Rep 13:1\u201316","journal-title":"Sci Rep"},{"key":"10662_CR28","doi-asserted-by":"crossref","first-page":"652544","DOI":"10.3389\/fcell.2021.652544","volume":"9","author":"V Le Joncour","year":"2021","unstructured":"Le Joncour V, Guichet PO, Demb\u00e9l\u00e9 KP et al (2021) Targeting the Urotensin II\/UT G Protein-Coupled receptor to counteract angiogenesis and mesenchymal hypoxia\/necrosis in glioblastoma. Front Cell Dev Biol 9:652544","journal-title":"Front Cell Dev Biol"},{"key":"10662_CR29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1568009616666160621101248","volume":"17","author":"A Federico","year":"2017","unstructured":"Federico A, Zappavigna S, Dallio M, Misso G, Merlino F, Loguercio C, Novellino E, Grieco P, Caraglia M (2017) Urotensin-II receptor: A double identity receptor involved in vasoconstriction and in the development of digestive tract cancers and other tumors. Curr Cancer Drug Targets 17:109\u2013121","journal-title":"Curr Cancer Drug Targets"},{"key":"10662_CR30","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.12659\/MSM.890459","volume":"20","author":"O Balakan","year":"2014","unstructured":"Balakan O, Kalender ME, Suner A, Cengiz B, Oztuzcu S, Bayraktar R, Borazan E, Babacan T, Camci C (2014) The relationship between Urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med Sci Monit 20:1419\u20131425","journal-title":"Med Sci Monit"},{"key":"10662_CR31","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.3892\/ol.2016.5344","volume":"12","author":"DG Liu","year":"2016","unstructured":"Liu DG, Chen J, Wang HX, Li BX (2016) Increased expression of Urotensin II is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 12:4961\u20134968","journal-title":"Oncol Lett"},{"key":"10662_CR32","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.2217\/fon.15.249","volume":"11","author":"O De Cobelli","year":"2015","unstructured":"De Cobelli O, Buonerba C, Terracciano D et al (2015) Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol 11:3091\u20133098","journal-title":"Future Oncol"},{"key":"10662_CR33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jcb.22933","volume":"112","author":"P Grieco","year":"2011","unstructured":"Grieco P, Franco R, Bozzuto G et al (2011) Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J Cell Biochem 112:341\u2013353","journal-title":"J Cell Biochem"},{"issue":"14","key":"10662_CR34","doi-asserted-by":"crossref","first-page":"Page5636","DOI":"10.3390\/cancers14225636","volume":"2022","author":"W Yang","year":"2022","unstructured":"Yang W, Zhang T, Song X, Dong G, Xu L, Jiang F (2022) SNP-Target genes interaction perturbing the Cancer risk in the Post-GWAS. Cancers 2022(14):Page5636\u2013145636","journal-title":"Cancers"},{"key":"10662_CR35","first-page":"86","volume":"20","author":"K Arman","year":"2017","unstructured":"Arman K, Bozgeyik E, Dagli H, Igci YZ (2017) UTS2 (urotensin 2). Atlas Genet Cytogenet Oncol Haematol 20:86\u201391","journal-title":"Atlas Genet Cytogenet Oncol Haematol"},{"key":"10662_CR36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/postgradmedj-2016-134476","volume":"93","author":"J Zhao","year":"2017","unstructured":"Zhao J, Jiang J, Wang J, Liu L, Han XN, Chu SY, Xue L, Ding WH (2017) Genetic polymorphisms of UTS2 rs2890565 Ser89Asn in cardiac hypertrophy in Chinese Han population. Postgrad Med J 93:406\u2013413","journal-title":"Postgrad Med J"},{"key":"10662_CR37","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.peptides.2004.03.030","volume":"25","author":"S Suzuki","year":"2004","unstructured":"Suzuki S, Wenyi Z, Hirai M et al (2004) Genetic variations at Urotensin II and Urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides (NY) 25:1803\u20131808","journal-title":"Peptides (NY)"},{"key":"10662_CR38","doi-asserted-by":"crossref","first-page":"100789","DOI":"10.1016\/j.genrep.2020.100789","volume":"20","author":"A Kamal","year":"2020","unstructured":"Kamal A, Mohsen A, Kamal A, Siam I (2020) Study of the association between Urotensin 2 (p.T21M and p.S89N) variants and breast cancer in Egyptian patients. Gene Rep 20:100789","journal-title":"Gene Rep"},{"key":"10662_CR39","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s13277-015-3082-2","volume":"36","author":"O Yumrutas","year":"2015","unstructured":"Yumrutas O, Oztuzcu S, B\u00fcy\u00fckhatipoglu H et al (2015) The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. Tumor Biology 36:4427\u20134432","journal-title":"Tumor Biology"},{"key":"10662_CR40","doi-asserted-by":"crossref","unstructured":"Eeles RA, Olama AA, Al, Benlloch S et al (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics 2013 45:4 45:385\u2013391","DOI":"10.1038\/ng.2560"},{"key":"10662_CR41","doi-asserted-by":"publisher","unstructured":"Ozturk K, Onal MS, Efiloglu O, Nikerel E, Yildirim A, Telci D (2020) Association of 5\u2032UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis. https:\/\/doi.org\/10.1016\/j.gene.2020.144589. Gene","DOI":"10.1016\/j.gene.2020.144589"},{"key":"10662_CR42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/02713683.2012.688181","volume":"37","author":"S Okumus","year":"2012","unstructured":"Okumus S, Igci YZ, Taskin T et al (2012) Association between Thr21Met and Ser89Asn polymorphisms of the urotensin-II (UTS2) gene, diabetes mellitus, and diabetic retinopathy. Curr Eye Res 37:921\u2013929","journal-title":"Curr Eye Res"},{"key":"10662_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/cr.2009.33","volume":"19","author":"Z Li","year":"2009","unstructured":"Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y (2009) A partition-ligation-combination-subdivision Em algorithm for haplotype inference with multiallelic markers: update of the shesis (http:\/\/analysis.bio- x.cn). Cell Res 19:519\u2013523","journal-title":"Cell Res"},{"key":"10662_CR44","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/en.2003-0029","volume":"144","author":"M Matsushita","year":"2003","unstructured":"Matsushita M, Shichiri M, Fukai N, Ozawa N, Yoshimoto T, Takasu N, Hirata Y (2003) Urotensin II is an autocrine\/paracrine growth factor for the Porcine renal epithelial cell line, LLCPK1. Endocrinology 144:1825\u20131831","journal-title":"Endocrinology"},{"key":"10662_CR45","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0024-3205(02)02346-9","volume":"72","author":"K Tamura","year":"2003","unstructured":"Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y (2003) Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 72:1049\u20131060","journal-title":"Life Sci"},{"key":"10662_CR46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/hc2601.092848","volume":"104","author":"T Watanabe","year":"2001","unstructured":"Watanabe T, Pakala R, Katagiri T, Benedict CR (2001) Synergistic effect of Urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104:16\u201318","journal-title":"Circulation"},{"key":"10662_CR47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.regpep.2010.02.009","volume":"162","author":"D Guidolin","year":"2010","unstructured":"Guidolin D, Albertin G, Oselladore B, Sorato E, Rebuffat P, Mascarin A, Ribatti D (2010) The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1\/2 and PI3K signaling pathways. Regul Pept 162:26\u201332","journal-title":"Regul Pept"},{"key":"10662_CR48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.regpep.2011.08.001","volume":"172","author":"G Albertin","year":"2011","unstructured":"Albertin G, Guidolin D, Sorato E, Oselladore B, Tortorella C, Ribatti D (2011) Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells. Regul Pept 172:16\u201322","journal-title":"Regul Pept"},{"key":"10662_CR49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2174\/092986709787458515","volume":"16","author":"T Watanabe","year":"2009","unstructured":"Watanabe T, Arita S, Shiraishi Y, Suguro T, Sakai T, Hongo S, Miyazaki A (2009) Human Urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr Med Chem 16:550\u2013563","journal-title":"Curr Med Chem"},{"key":"10662_CR50","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s00125-003-1145-1","volume":"46","author":"Z Wenyi","year":"2003","unstructured":"Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J, Oka Y (2003) Role of Urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46:972\u2013976","journal-title":"Diabetologia"},{"key":"10662_CR51","doi-asserted-by":"publisher","unstructured":"Haider M, Lange PH (2016) Breast and Prostate Cancers: A Comparison of Two Endocrinologic Malignancies, Second Edi. Prostate Cancer: Science and Clinical Practice: Second Edition. https:\/\/doi.org\/10.1016\/B978-0-12-800077-9.00019-0","DOI":"10.1016\/B978-0-12-800077-9.00019-0"},{"key":"10662_CR52","first-page":"1259","volume":"35","author":"ET Ellis","year":"2024","unstructured":"Ellis ET, Fairman BJ, Stahr SD, Bensen JT, Mohler JL, Song L, Butler EN, Su LJ, Hsu PC (2024) Cigarette smoking and prostate cancer aggressiveness among African and European American men. Cancer Causes Control 35:1259\u20131269","journal-title":"Cancer Causes Control"},{"key":"10662_CR53","doi-asserted-by":"publisher","unstructured":"Al-Fayez S, El-Metwally A (2023) Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies. https:\/\/doi.org\/10.18332\/tid\/157231","DOI":"10.18332\/tid\/157231"},{"key":"10662_CR54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1200\/JCO.2025.43.5_suppl.249","volume":"43","author":"C Dinckal","year":"2025","unstructured":"Dinckal C, Guc ZG, Yilmaz HE et al (2025) Clinical significance of Urotensin 2 plasma level in patients diagnosed with prostate cancer. J Clin Oncol 43:249\u2013249","journal-title":"J Clin Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10662-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:34:22Z","timestamp":1766853262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10662-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10662"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10662-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments have been approved by the Ethical Committee of Istanbul Medeniyet University G\u00f6ztepe Education and Research Hospital (Decision No: 2022\/0113). This study complies with Declaration of Helsinki and approved by the Ethical Committee of Istanbul Medeniyet University G\u00f6ztepe Education and Research Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants were informed with written consent form before participation to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"572"}}